Gabather AB submits a Clinical Trial Application to further advance the development of GT-002
Gabather’s clinical development with its lead compound GT-002 aims at a Proof-of-Concept (PoC) study addressing cognitive deficits in depression as the first indication. A single-dose target engagement study in healthy volunteers using electroencephalography (EEG) and the safety data acquired from the Multiple ascending dose study (MAD) will guide the design of this efficacy study in patients in an adaptive design. As the next step in this clinical development programme, Gabather AB has today submitted an application to the regulatory authorities in Portugal for the start of a double-